hNPC 01
Alternative Names: hNPC-01Latest Information Update: 16 Aug 2026
At a glance
- Originator Hopstem Biotechnology
- Class Induced pluripotent stem cell therapies; Neural stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Ischaemic stroke
- Preclinical Cerebral palsy; Epilepsy; Haemorrhagic stroke; Traumatic brain injuries
Most Recent Events
- 06 Aug 2026 Preclinical trials in Cerebral palsy in China (Parenteral), prior to August 2026 (Hopstem Biotechnology pipeline, August 2026)
- 06 Aug 2026 Preclinical trials in Traumatic brain injuries in China (Parenteral), prior to August 2026 (Hopstem Biotechnology pipeline, August 2026)
- 29 Jul 2026 Preclinical trials in Haemorrhagic stroke in China (Parenteral), prior to July 2026